Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two pharmaceutical agents, acetylsalicylic acid (commonly known as aspirin) and duloxetine. Acetylsalicylic acid is a nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits cyclooxygenase-1 and -2 (COX-1/COX-2), leading to decreased synthesis of prostaglandins and thromboxanes, which results in analgesic, antipyretic, anti-inflammatory, and antiplatelet effects. Duloxetine is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) that increases the levels of these neurotransmitters in the central nervous system by inhibiting their reuptake at synaptic clefts. This dual mechanism provides antidepressant effects as well as pain modulation. The combination may be considered for patients with comorbid pain conditions requiring both an NSAID for inflammation/pain relief and an SNRI for neuropathic pain or mood disorders; however, caution is warranted due to increased risk of gastrointestinal bleeding when combining SNRIs with NSAIDs like aspirin[5][6]. There are no widely recognized brand names or fixed-dose products containing this exact combination.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetylsalicylic acid + duloxetine.